InnoCare Out-licenses BTK Inhibitor for MS to Biogen in $937 Million Deal
publication date: Jul 13, 2021
Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Biogen, which will have rights to orelabrutinib in multiple sclerosis and other specified autoimmune diseases, will pay $125 million upfront and up to $812.5 million in milestones, plus royalties. Thirty years ago, Biogen' Avonix was the first biologic approved for MS, and it currently markets five therapies for the disease. Innocare has started a global placebo-controlled Phase II trial of orelabrutinib in patients with relapsing-remitting MS. More details....
Stock Symbols: (HK: 09969) (NSDQ: BIIB)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.